H
Heidi Chen
Researcher at Vanderbilt University Medical Center
Publications - 147
Citations - 6492
Heidi Chen is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 33, co-authored 138 publications receiving 5275 citations. Previous affiliations of Heidi Chen include United States Department of Veterans Affairs & Georgia Institute of Technology.
Papers
More filters
Journal ArticleDOI
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris,Bruce E. Johnson,Lynne D. Berry,David J. Kwiatkowski,A. John Iafrate,Ignacio I. Wistuba,Marileila Varella-Garcia,Wilbur A. Franklin,Samuel J. Aronson,Pei Fang Su,Yu Shyr,D. Ross Camidge,Lecia V. Sequist,Bonnie S. Glisson,Fadlo R. Khuri,Edward B. Garon,William Pao,Charles M. Rudin,Joan H. Schiller,Eric B. Haura,Mark A. Socinski,Keisuke Shirai,Heidi Chen,Giuseppe Giaccone,Giuseppe Giaccone,Marc Ladanyi,Kelly Kugler,John D. Minna,Paul A. Bunn +28 more
TL;DR: The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.
Journal ArticleDOI
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
Todd W. Miller,Bryan T. Hennessy,Ana M. Gonzalez-Angulo,Emily M. Fox,Gordon B. Mills,Heidi Chen,Catherine F. Higham,Carlos Garcia-Echeverria,Yu Shyr,Carlos L. Arteaga +9 more
TL;DR: The data suggest that upon adaptation to hormone deprivation, breast cancer cells rely heavily on PI3K signaling, and imply that acquired resistance to endocrine therapy in breast cancer may be abrogated by combination therapies targeting both ER andPI3K pathways.
Journal ArticleDOI
Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The lung cancer mutation consortium experience
Lynette M. Sholl,Dara L. Aisner,Marileila Varella-Garcia,Lynne D. Berry,Dora Dias-Santagata,Ignacio I. Wistuba,Heidi Chen,Junya Fujimoto,Kelly Kugler,Wilbur A. Franklin,A. John Iafrate,Marc Ladanyi,Mark G. Kris,Bruce E. Johnson,Paul A. Bunn,John D. Minna,David J. Kwiatkowski +16 more
TL;DR: Multi-institutional molecular analysis across multiple platforms, sample types, and institutions can yield consistent results and novel clinicopathological observations in Lung Cancer Mutation Consortium patients.
Journal ArticleDOI
SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival
Mohamed Hassanein,Megan D. Hoeksema,Masakazu Shiota,Jun Qian,Bradford K. Harris,Heidi Chen,Jonathan E. Clark,William E. Alborn,Rosana Eisenberg,Pierre P. Massion +9 more
TL;DR: Results suggest that SLC1A5 plays a key role in Gln transport controlling lung cancer cells' metabolism, growth, and survival, an effect mediated in part by mTOR signaling.
Journal ArticleDOI
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly,Nerina T. McDonald,Heidi Chen,Sandra Ortiz-Cuaran,Lukas C. Heukamp,Yingjun Yan,Alexandra Florin,Luka Ozretić,Diana Lim,Lu Wang,Zhao Chen,Xi Chen,Pengcheng Lu,Paul K. Paik,Ronglai Shen,Hailing Jin,Reinhard Buettner,Sascha Ansén,Sven Perner,Michael Brockmann,Marc Bos,Jürgen Wolf,Masyar Gardizi,Gavin M. Wright,Benjamin Solomon,Prudence A. Russell,Toni Maree Rogers,Yoshiyuki Suehara,Monica Red-Brewer,Rudy Tieu,Elisa de Stanchina,Qingguo Wang,Zhongming Zhao,David H. Johnson,Leora Horn,Kwok-Kin Wong,Roman K. Thomas,Marc Ladanyi,William Pao +38 more
TL;DR: Data support a role for the IGF-1R–IRS-1 pathway in both ALK TKI–sensitive and ALKTKI–resistant states and provide a biological rationale for further clinical development of dual ALK and IGF- 1R inhibitors.